{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:12:29Z","timestamp":1792800749554,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.resinv.2014.06.005","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T00:30:41Z","timestamp":1406680241000},"page":"330-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance"],"prefix":"10.1016","volume":"52","author":[{"given":"Gouji","family":"Toyokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2014.06.005_bib1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/JTO.0b013e3181e452b9","article-title":"Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002","volume":"5","author":"Sawabata","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(13)61502-0","article-title":"Management of non-small-cell lung cancer: recent developments","volume":"382","author":"Reck","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2014.06.005_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J"},{"key":"10.1016\/j.resinv.2014.06.005_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib6","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib8","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10555-012-9391-7","article-title":"Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation\u2014diversity, ductility, and destiny","volume":"31","author":"Suda","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.resinv.2014.06.005_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2014.06.005_bib12","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrclinonc.2012.43","article-title":"Treating ALK-positive lung cancer\u2014early success and future challenges","volume":"9","author":"Camidge","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.2013.200","article-title":"Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer","volume":"95","author":"Solomon","year":"2013","journal-title":"Clin Phamacol Ther"},{"key":"10.1016\/j.resinv.2014.06.005_bib17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.onc.1200849","article-title":"Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system","volume":"14","author":"Iwahara","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.resinv.2014.06.005_bib18","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u05f3s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.resinv.2014.06.005_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/sj.npp.1301446","article-title":"Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications","volume":"33","author":"Bilsland","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.resinv.2014.06.005_bib20","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1074\/jbc.M007333200","article-title":"Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogene-activated protein kinase pathway","volume":"276","author":"Souttou","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2014.06.005_bib21","first-page":"866","article-title":"The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma","volume":"3","author":"Le Beau","year":"1989","journal-title":"Leukemia"},{"key":"10.1016\/j.resinv.2014.06.005_bib22","first-page":"2776","article-title":"Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors","volume":"59","author":"Griffin","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/modpathol.2010.213","article-title":"Renal cell carcinoma with novel VCL\u2013ALK fusion: new representative of ALK-associated tumor spectrum","volume":"24","author":"Debelenko","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.resinv.2014.06.005_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib25","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","article-title":"Exon array profiling detects EML4\u2013ALK fusion in breast, colorectal, and non-small cell lung cancers","volume":"7","author":"Lin","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2014.06.005_bib27","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1158\/0008-5472.CAN-10-4041","article-title":"Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene","volume":"71","author":"Murugan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib28","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1349-7006.2008.00972.x","article-title":"Non-solid oncogenes in solid tumors: EML4\u2013ALK fusion genes in lung cancer","volume":"99","author":"Mano","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.resinv.2014.06.005_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.resinv.2014.06.005_bib30","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4\u2013ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resinv.2014.06.005_bib31","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-3260","article-title":"Differential protein stability and ALK inhibitor sensitivity of EML4\u2013ALK fusion variants","volume":"18","author":"Heuckmann","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib32","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","article-title":"KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer","volume":"15","author":"Takeuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib33","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.resinv.2014.06.005_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/JTO.0000000000000087","article-title":"HIP1-ALK, a novel ALK fusion variant that responds to crizotinib","volume":"9","author":"Fang","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib35","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-11-2947","article-title":"A prospective PCR-based screening for the EML4\u2013ALK oncogene in non-small cell lung cancer","volume":"18","author":"Soda","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib36","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib37","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00428-013-1413-5","article-title":"ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement","volume":"462","author":"Kim","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.resinv.2014.06.005_bib40","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/JTO.0b013e3182762bcb","article-title":"First case of combined small-cell lung cancer with adenocarcinoma harboring EML4\u2013ALK fusion and an exon 19 EGFR mutation in each histological component","volume":"7","author":"Toyokawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.lungcan.2013.05.022","article-title":"An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4\u2013ALK fusion gene","volume":"81","author":"Toyokawa","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2014.06.005_bib42","first-page":"375","article-title":"Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer","volume":"7","author":"Iwama","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.resinv.2014.06.005_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2013.01.004","article-title":"ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH","volume":"15","author":"Minca","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.resinv.2014.06.005_bib44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/JTO.0b013e31827db604","article-title":"Cobined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas","volume":"8","author":"Sholl","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1371\/journal.pone.0052261","article-title":"Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients","volume":"8","author":"Martinez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2014.06.005_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e318274a83e","article-title":"Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent","volume":"8","author":"Conklin","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2012.03.004","article-title":"Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients","volume":"77","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2014.06.005_bib48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/JTO.0000000000000072","article-title":"Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances","volume":"9","author":"Cabillic","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib49","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMc1013325","article-title":"More on crizotinib","volume":"364","author":"Chihara","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib50","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.resinv.2014.06.005_bib51","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-07-6186","article-title":"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors","volume":"68","author":"McDermott","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib52","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.resinv.2014.06.005_bib53","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2012.42.4556","article-title":"Response to crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"30","author":"Komiya","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib54","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.resinv.2014.06.005_bib56","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib57","unstructured":"Inoue A, Nishio M, Kiura K, et al. One-year follow-up of a Phase I\/II study of a highly selective ALK inhibitor CH5424802\/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC). In: Proceedings of WCLC; 2013. P3.11-034."},{"key":"10.1016\/j.resinv.2014.06.005_bib58","unstructured":"Gadgeel S, Ou SH, Chiappori AA, et al. A phase 1 dose escalation study of a new ALK inhibitor, CH5424802\/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG\/NP28761, NCT01588028). In: Proceedings of WCLC; 2013. Abstract16.06."},{"key":"10.1016\/j.resinv.2014.06.005_bib59","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.resinv.2014.06.005_bib60","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib61","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.resinv.2014.06.005_bib62","doi-asserted-by":"crossref","unstructured":"Seto T, Murakami H, Hirai F, et al. Phase I study of the ALK inhibitor LDK378 in Japanes patients with advanced, ALK-rearranged NSCLC and other tumors harboring genetic ALK alterations. In: Proceedings of WCLC; 2013. P1.11-007.","DOI":"10.1093\/annonc\/mdu349.73"},{"key":"10.1016\/j.resinv.2014.06.005_bib63","doi-asserted-by":"crossref","unstructured":"Rivera VM, Wang F, Anjum R, et al. AP26113 is a dual ALK\/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. In: Proceedings of the 103rd AACR Annual Meeting, AACR\u05f312. Chicago, USA; 2012.","DOI":"10.1158\/1538-7445.AM2012-1794"},{"key":"10.1016\/j.resinv.2014.06.005_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8031","article-title":"First-in-human dose-finding study of the ALK\/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results","volume":"31","author":"Camidge","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib65","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-11-A227","article-title":"Antitumor activities of ASP3026 against EML4\u2013ALK-dependent tumor models","volume":"10","author":"Kuromitsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.resinv.2014.06.005_bib66","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-10-3879","article-title":"Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors","volume":"71","author":"Lovly","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib67","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4\u2013ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib68","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.resinv.2014.06.005_bib69","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib70","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1747-0285.2011.01239.x","article-title":"Crizotinib-resistant mutants of EML4\u2013ALK identified through an accelerated mutagenesis screen","volume":"78","author":"Zhang","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.resinv.2014.06.005_bib71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","article-title":"ALK inhibitors in the treatment of advanced NSCLC","volume":"40","author":"Gridelli","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.resinv.2014.06.005_bib72","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib73","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/JTO.0b013e318288dc2d","article-title":"Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4\u2013ALK rearrangement","volume":"8","author":"Maillet","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib74","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1097\/JTO.0b013e3182843771","article-title":"Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer","volume":"8","author":"Kaneda","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib75","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/JTO.0000000000000029","article-title":"The central nervous system as a sanctuary site in ALK-positive non-small cell lung cancer","volume":"8","author":"Gainor","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib76","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/JTO.0000000000000038","article-title":"Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer","volume":"8","author":"Peled","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib77","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2014.06.005_bib78","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1097\/JTO.0b013e318293d96f","article-title":"Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies","volume":"8","author":"Kobayashi","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2014.06.005_bib79","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4161\/cbt.28162","article-title":"Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer","volume":"15","author":"Ji","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.resinv.2014.06.005_bib80","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harbouring the fusion oncogene EML4\u2013ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.resinv.2014.06.005_bib81","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1078-0432.CCR-13-1733","article-title":"Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2014.06.005_bib82","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/JTO.0000000000000113","article-title":"Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?","volume":"9","author":"Gouji","year":"2014","journal-title":"J Thorac Oncol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534514000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534514000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T02:34:56Z","timestamp":1649817296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534514000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S2212534514000793"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2014.06.005","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2014.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Japanese Respiratory Society. Published by Elsevier Japan KK All rights reserved.","name":"copyright","label":"Copyright"}]}}